Opus Genetics, Inc.
- Last sale
- Nov 12, 2026 · -5.58%
- Market cap
- $392.42M
- 96.65M shares
- Filings
- 1,051
Q3 2026+29.1% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY20 yoy
Q3 2026N/M FY25 yoy
Q3 2026+48.7% FY25 yoy
- $392.42M
- —
- 49.6×
- 10.2×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $14,196,000 | reported | |
| FY 2024 | 2024-12-31 | $10,992,000 | reported | |
| FY 2023 | 2023-12-31 | $19,049,000 | reported | |
| FY 2022 | 2022-12-31 | $39,850,000 | reported | |
| FY 2021 | 2021-12-31 | $589,000 | reported | |
| FY 2020 | 2020-12-31 | $0 | reported | |
| FY 2019 | 2019-12-31 | $3,000,000 | reported | |
| FY 2013 | 2013-12-31 | $0 | reported | |
| FY 2012 | 2012-12-31 | $0 | reported | |
| FY 2011 | 2011-12-31 | $0 | reported | |
| FY 2010 | 2010-12-31 | $0 | reported | |
| FY 2009 | 2009-12-31 | $0 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2011 | — | $0.00 | $0.00 | — | 95.35M sh | +13.3% | — |
| FY2010 | — | $0.00 | $0.00 | — | 84.16M sh | — | — |
| FY2009 | — | $0.00 | $0.00 | — | — | — | — |
Pharmaceutical preparations
Opus Genetics, Inc. is the 158th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
QUREuniQure N.V.$16.1M40.6%1,236.0%$1.7B
IRDOpus Genetics, Inc. (this company)$14.2M29.1%349.3%$392.4M
ABUSArbutus Biopharma Corp$14.1M128.2%237.9%$617.8MPYXSPyxis Oncology, Inc.$13.9M14.2%574.5%$189.0MCVSICV Sciences, Inc.$13.8M12.2%6.9%$2.4MPTNPalatin Technologies Inc$13.2M—63.5%$12.2MTNXPTonix Pharmaceuticals Holding Corp.$13.1M29.8%946.2%$62.6MEVMNEvommune, Inc.$13.0M85.7%529.8%$241.9MEMMAEmmaus Life Sciences, Inc.$12.5M25.2%60.2%$4.2MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR